NDTV Profit

Zydus Cadila Acquires US-Based Sentynl Therapeutics

The transaction will be EPS (earnings per share) accretive, Zydus Cadila said in a statement.
EMAIL
COMMENTS
Zydus Cadila Acquires US-Based Sentynl Therapeutics
New Delhi: Zydus Cadila on Thursday said it has acquired Sentynl Therapeutics, a US-based pharma company specialised in marketing of products in the pain management segment.

The transaction will be EPS (earnings per share) accretive, Zydus Cadila said in a statement.

With this acquisition, it said the company makes a foray into the specialty pain market in the US valued at $8 billion.

"It gains access to the specialty distribution network and a large prescriber base....This acquisition will also enable the Zydus group to leverage its existing assets in the US," it added.

Speaking on the development Pankaj R Patel, Chairman and Managing Director, Zydus Cadila said: "...the acquisition of Sentynl opens up a new business avenue for us in the specialty prescription segment in the US."

It said the acquisition is solely funded by Bank of Tokyo-Mitsubishi UFJ.

Leerink Partners LLC acted as exclusive financial advisor to Sentynl on the transaction.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

For latest news on Business, like us on Facebook and follow us on Twitter.
ALSO READ 26 Chartered Accountants Under Watch In Crackdown On Shell Companies

Advertisement

Advertisement

GAINERS / LOSERS